Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor Conference September 30th

Download as PDF

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will participate in the BTIG Emerging Technologies in Healthcare Diagnostics investor conference taking place September 29th and 30th in New York.

Interim Chief Executive Officer Michael Goldberg, M.D., will participate in the following panels on Tuesday, September 30th:

  • Cell Specific Imaging/Biopsy Assistance
  • Innovations in Diagnosing Alzheimer’s
  • Laboratory vs. Hospital Launch

The conference is organized as a series of panel discussions designed to inform investors on trends, technologies, and organizations shaping the healthcare diagnostics industry. As a result of the format, a webcast will not be available.

About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, Executive VP & CFO, 614-822-2330
or
Sharon Correia, Associate Director, Corporate Communications, 978-655-2686

Source: Navidea Biopharmaceuticals, Inc.

Released September 29, 2014